BRTX Logo

BioRestorative Therapies, Inc. (BRTX) 

NASDAQ
Market Cap
$9.78M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
145 of 774
Rank in Industry
92 of 432

Largest Insider Buys in Sector

BRTX Stock Price History Chart

BRTX Stock Performance

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase …

Insider Activity of BioRestorative Therapies, Inc.

Over the last 12 months, insiders at BioRestorative Therapies, Inc. have bought $470,956 and sold $2,752 worth of BioRestorative Therapies, Inc. stock.

On average, over the past 5 years, insiders at BioRestorative Therapies, Inc. have bought $420,111 and sold $11,518 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Broadrick Dale (10 percent owner) — $460,727. Silva Francisco (VP of Research and Development) — $10,229.

The last purchase of 6,600 shares for transaction amount of $8,250 was made by Silva Francisco (VP of Research and Development) on 2024‑04‑09.

List of Insider Buy and Sell Transactions, BioRestorative Therapies, Inc.

2024-10-28Sale10 percent owner
1,112
0.0157%
$1.58$1,7570.00%
2024-04-09PurchaseVP of Research and Development
6,600
0.0952%
$1.25$8,250+19.53%
2024-04-08PurchaseVP of Research and Development
1,708
0.0228%
$1.16$1,979+19.53%
2024-02-09Purchase10 percent owner
86,041
1.4895%
$1.32$113,574+5.93%
2024-02-08Purchase10 percent owner
157,585
2.6821%
$1.30$204,508+11.72%
2024-02-08Purchase10 percent owner
73,959
1.2124%
$1.25$92,449+11.72%
2024-02-07Purchase10 percent owner
36,374
0.6583%
$1.38$50,196+0.35%
2023-12-01Sale10 percent owner
250
0.0053%
$1.88$469-18.62%
2023-11-27Sale10 percent owner
278
0.0059%
$1.89$525-18.42%
2023-09-15Purchase10 percent owner
10,000
0.213%
$1.66$16,600-3.89%
2023-09-15PurchasePresident, CEO, COB
2,200
0.048%
$1.70$3,740-3.89%
2023-09-14Purchase10 percent owner
10,000
0.2062%
$1.54$15,400+0.47%
2023-09-13PurchasePresident, CEO, COB
800
0.0161%
$1.53$1,226+7.00%
2023-09-07Purchase10 percent owner
2,000
0.044%
$1.86$3,720-14.81%
2023-09-06PurchasePresident, CEO, COB
2,887
0.0638%
$1.96$5,659-15.13%
2023-08-31PurchaseVP of Research and Development
4,954
0.1071%
$2.22$10,998-26.36%
2023-07-28Purchase10 percent owner
500
0.016%
$2.89$1,445-41.05%
2023-07-27Purchase10 percent owner
1,000
0.031%
$2.80$2,800-33.68%
2023-07-25PurchasePresident, CEO, COB
4,200
0.1134%
$2.44$10,248-30.45%
2023-03-31PurchaseVP of Research and Development
747
0.0216%
$3.56$2,659-42.79%

Insider Historical Profitability

<0.0001%
Broadrick Dale10 percent owner
445933
6.4442%
$1.41794<0.0001%
Silva FranciscoVP of Research and Development
155759
2.2509%
$1.41211<0.0001%
Westbury Trust10 percent owner
3115000
45.015%
$1.4110
Desmarais John M
455000
6.5752%
$1.4120
ALSTODT LANCEPresident, CEO, COB
189505
2.7385%
$1.41330<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.